2 búsqueda de la palabra clave 'Hypoglycemia'

Disglucemia asociada a fluoroquinolonas: Una revision estructurada / Elkyn Johan Granados Vega  

Público ISBD Título : Disglucemia asociada a fluoroquinolonas: Una revision estructurada Otros títulos : Hypo or hyperglycemia associated with fluoroquinolone use Tipo de documento : documento electrónico Autores : Elkyn Johan Granados Vega, Fecha de publicación : 2018 Títulos uniformes : Revista Médica de Chile Idioma : Español (spa) Palabras clave : Hyperglycemia  Hypoglycemia  Quinolones Resumen : Fluoroquinolone type antimicrobials can cause hypo or hyperglycemia in certain patients. We performed a structured review about this side effect, searching articles published in English or Spanish with full text access in PubMed/Medline. The following MESH terms were used: Hypoglycemia, Hyperglycemia, Quinolones, Ciprofloxacin, Levofloxacin, Moxifloxacin. Additionally, we evaluated the clinical relevance of potential drug interactions, based on the probability of occurrence and the severity of the interaction effect. We obtained 42 publications about the issue; 22 references were selected, where the severity of the interaction in patients with risk factors was evaluated. Patients receiving antidiabetic medications and with risk factors such as advanced age and renal failure may be more likely to have a severe hypoglycemia. In these patients, this drug interaction should be considered clinically relevant since its risk is high or very high. Mención de responsabilidad : Johan Granados, Mauricio Ceballos, Pedro Amariles Referencia : Rev Med Chil. 2018 May;146(5):618-626. DOI (Digital Object Identifier) : 10.4067/s0034-98872018000500618 PMID : 30148925 En línea : http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6181 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4711 Disglucemia asociada a fluoroquinolonas: Una revision estructurada = Hypo or hyperglycemia associated with fluoroquinolone use [documento electrónico] / Elkyn Johan Granados Vega,  . - 2018. Obra : Revista Médica de Chile Idioma : Español (spa) Palabras clave : Hyperglycemia  Hypoglycemia  Quinolones Resumen : Fluoroquinolone type antimicrobials can cause hypo or hyperglycemia in certain patients. We performed a structured review about this side effect, searching articles published in English or Spanish with full text access in PubMed/Medline. The following MESH terms were used: Hypoglycemia, Hyperglycemia, Quinolones, Ciprofloxacin, Levofloxacin, Moxifloxacin. Additionally, we evaluated the clinical relevance of potential drug interactions, based on the probability of occurrence and the severity of the interaction effect. We obtained 42 publications about the issue; 22 references were selected, where the severity of the interaction in patients with risk factors was evaluated. Patients receiving antidiabetic medications and with risk factors such as advanced age and renal failure may be more likely to have a severe hypoglycemia. In these patients, this drug interaction should be considered clinically relevant since its risk is high or very high. Mención de responsabilidad : Johan Granados, Mauricio Ceballos, Pedro Amariles Referencia : Rev Med Chil. 2018 May;146(5):618-626. DOI (Digital Object Identifier) : 10.4067/s0034-98872018000500618 PMID : 30148925 En línea : http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6181 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4711

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001185	AC-2018-126	Archivo digital	Producción Científica	Artículos científicos	Disponible

Glucagon like peptide 1 receptor agonists: a therapy for diabetes management / Natalia Andrea Rojas Henao ; Elkyn Johan Granados Vega    

Público ISBD Título : Glucagon like peptide 1 receptor agonists: a therapy for diabetes management Otros títulos : Agonistas del receptor péptido 1 similar al glucagón: una terapia para el control de la diabetes Tipo de documento : documento electrónico Autores : Natalia Andrea Rojas Henao, ; Elkyn Johan Granados Vega, Fecha de publicación : 2018 Títulos uniformes : CES Medicina Idioma : Inglés (eng) Palabras clave : Diabetes Mellitus  Type 2  Glucagon-like peptide-1  Hypoglycemia  Hemoglobin A  glycosylated Resumen : Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A. Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release. Results: The GLP1 receptor agonist are agents involved with glycemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes. Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic control, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety. Mención de responsabilidad : Natalia Andrea Rojas, Elkyn Johan Granados Vega DOI (Digital Object Identifier) : 10.21615/cesmedicina.32.1.3 Derechos de uso : CC BY-NC-ND En línea : https://revistas.ces.edu.co/index.php/medicina/article/view/3983 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4733 Glucagon like peptide 1 receptor agonists: a therapy for diabetes management = Agonistas del receptor péptido 1 similar al glucagón: una terapia para el control de la diabetes [documento electrónico] / Natalia Andrea Rojas Henao, ; Elkyn Johan Granados Vega,  . - 2018. Obra : CES Medicina Idioma : Inglés (eng) Palabras clave : Diabetes Mellitus  Type 2  Glucagon-like peptide-1  Hypoglycemia  Hemoglobin A  glycosylated Resumen : Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A. Methods: A bibliographic search was made on Medline® about pharmacology of the agonist glucagon-like peptide-1 receptor , Liraglutide, Lixisenatide, Albiglutide, Exenatide, Exenatide with long-acting release. Results: The GLP1 receptor agonist are agents involved with glycemic balance, weight loss induction and are associated with lower risk of hypoglycemia. They have shown efficacy in the treatment of hypoglycemia in patients with type-2 diabetes. Conclusions: GLP1 receptor agonist are part of the therapies for diabetes that have shown benefits in metabolic control, effectiveness in weight reduction and changes in glycated hemoglobin. More studies are needed to evaluate its long-term safety. Mención de responsabilidad : Natalia Andrea Rojas, Elkyn Johan Granados Vega DOI (Digital Object Identifier) : 10.21615/cesmedicina.32.1.3 Derechos de uso : CC BY-NC-ND En línea : https://revistas.ces.edu.co/index.php/medicina/article/view/3983 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4733

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001207	AC-2018-151	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2018-151.pdf Adobe Acrobat PDF